TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24346608
Drug: Quetiapine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine with adjunctive personalized treatments (APTs)
Study: 24346608
Drug: Lithium with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium with adjunctive personalized treatments (APTs)
Study: 20171653
Drug: Montelukast (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (4 mg) for 3 months
Study: 16366762
Drug: Isradipine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (30 mg sustained release nightly plus 15 mg immediate release 2 hr before cocaine infusion)
Study: 9218198
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of verapamil and trandolapril
Study: 31959609
Drug: HEV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HEV vaccine (HEV 239, Hecolin)
Study: 14557958
Drug: Control vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control vaccine (hepatitis B vaccine)
Study: 29215606
Drug: Nutrient enriched
Normalized name: Votrient
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Nutrient enriched breakfast bar (containing α‐Linolenic acid, l‐tyrosine, l‐theanine, vitamins, minerals and 21.5 mg of caffeine)
Study: 25746294
Drug: 24 days
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 24 days of 3mg drospirenone (DRSP)/20 mcg EE, followed by 4 placebo (PBO)‐pill days (DRSP/EE+4 days PBO)
Study: 25746294
Drug: 21 days
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 21 days of 100 mcg levonorgestrel (LNG)/20 mcg EE, followed by 7 PBO‐pill days (LNG/EE+7 days PBO)
Study: 21453379
Drug: Adapted U.S.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapted U.S. model of pharmaceutical care (n=128)
Study: 11416745
Drug: 200 ml
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 ml milk before exercise SPECT and after injection for rest SPECT acquisition (Group B) plus a standard solid and fluid meal
Study: 11416745
Drug: 200 ml
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 ml milk before exercise SPECT and after injection for rest SPECT acquisition (Group A)
Study: 8440858
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy sessions three times weekly for 4 months, lasting 30 minutes each, consisting of functional activity and general conditioning exercises tailored to individual needs.
Study: 8440858
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy sessions three times weekly for 4 months.
Study: 8440858
Drug: Structured social
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured social visits three times weekly to control for potential Hawthorne effects.
Study: 8440858
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy intervention costs and incremental health care utilization.
Study: 24956971
Drug: Chlorthalidone (12.5-25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone (12.5-25 mg daily, group D)
Study: 24956971
Drug: Other antihypertensive
Normalized name: Other antihypertensives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other antihypertensive medications (group A)
Study: 16487390
Drug: Active medication
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active medication (ranitidine plus cisapride)
Study: 12871446
Drug: Enoxaparin 40
Normalized name: ENOXAPARIN 40MG/0.4ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 40 mg daily subcutaneous injections
Study: 10831196
Drug: Lidocaine 4%
Normalized name: Lidocaine 4% Patch
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine 4% solution
Study: 8018455
Drug: 0.04 mg
Normalized name: sulfur 0.04 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.04 mg kg‐1 enalaprilat (low‐dose, n = 10)
Study: 8018455
Drug: 0.08 mg
Normalized name: mestranol 0.08 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.08 mg kg‐1 enalaprilat (high‐dose, n = 10)
Study: 8018455
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution as placebo (control group, n = 10)
Study: 30747745
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate administration for longer than 18 hours, given within 12 hours of delivery, maintaining a maternal serum level of 4.1 mg/dl.
Study: 25417403
Drug: Fuzi-cake-separated moxibustion
Normalized name: serrated swimming crab, cooked preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fuzi-cake-separated moxibustion at Guanyuan (CV 4) and Zhongji (CV 3), 20 min twice a day for 3 days before operation
Study: 19243424
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eslicarbazepine acetate 1,200 mg
Study: 11170945
Drug: Clinafloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinafloxacin (200 mg every 12 h)
Study: 11170945
Drug: Imipenem (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem (500 mg every 6 h)
Study: 2382874
Drug: Adenosine inhalation
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine inhalation tests on day A
Study: 2382874
Drug: Saline inhalation
Normalized name: Broncho Saline Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline inhalation test on day B
Study: 2382874
Drug: Methacholine inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methacholine inhalation tests on day C
Study: 7362945
Drug: Prophylactic clindamycin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic clindamycin, 150 mg 6-hourly for 5 days
Study: 31706052
Drug: Alendronate (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (70 mg weekly) + daily elemental calcium (500 mg) + cholecalciferol (1000 IU)
Study: 31706052
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (daily elemental calcium (500 mg) + cholecalciferol (1000 IU) only)
Study: 21836511
Drug: sirolimus, mycophenolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: sirolimus, mycophenolate mofetil and steroids
Study: 19680260
Drug: Azelnidipine (first-line
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelnidipine (first-line therapy)
Study: 11159250
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of 0.125% bupivacaine with clonidine 1 microg/mL and sufentanil 0.1 microg/mL at 10 mL/h (Group 1)
Study: 11159250
Drug: PCA boluses
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA boluses of 10 mL/h of 0.125% bupivacaine with clonidine 1 microg/mL and sufentanil 0.1 microg/mL (Group 2)
Study: 11159250
Drug: PCA boluses
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA boluses of 5 mL per 30 min of 0.125% bupivacaine with clonidine 1 microg/mL and sufentanil 0.1 microg/mL (Group 3)
Study: 9626725
Drug: Collaborative management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collaborative management programme including patient education, on-site mental health treatment, adjustment of antidepressant medication, behavioural activation and monitoring of medication adherence
Study: 21969666
Drug: Sequential scanning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential scanning in group A
Study: 21969666
Drug: Sequential scanning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential scanning in group B
Study: 21969666
Drug: Narrow-window prospective
Normalized name: narrowleaf marshelder pollen extract
DrugBank: Iva angustifolia pollen (DB10968)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrow-window prospective sequential scanning in group A
Study: 21969666
Drug: Wide-window prospective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wide-window prospective sequential scanning in group B
Study: 18847416
Drug: New immunosuppressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: New immunosuppressive drugs (specific drugs not mentioned)
Study: 18847416
Drug: Low-dose or
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose or calcineurin inhibitor-free regimens
Study: 8958267
Drug: Standard immunosuppression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard immunosuppression (cyclosporine and steroids)
Study: 1540881
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy with 5‐fluorouracil (5‐FU), doxorubicin, and mitomycin C (FAM)
Study: 1540881
Drug: Sequential chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential chemotherapy with mitomycin C, followed by doxorubicin on disease progression, followed by 5‐FU
Study: 1540881
Drug: Secondary therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secondary therapy with doxorubicin alone
Study: 1540881
Drug: Tertiary therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tertiary therapy with 5‐FU alone
Study: 1540881
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (FAM)
Study: 26093535
Drug: High-dose green
Normalized name: acid green 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose green tea extract (EGCG) at a daily dosage of 856.8 mg
Study: 26093535
Drug: High-dose green
Normalized name: acid green 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose green tea extract (EGCG)
Study: 24925303
Drug: Galacto‐oligosaccharides (GOS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galacto‐oligosaccharides (GOS) (2·5 g; three times per d) during and 7 d after AMX treatment
Study: 24925303
Drug: Placebo (maltodextrin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (maltodextrin, n 6) (2·5 g; three times per d) during and 7 d after AMX treatment
Study: 9347244
Drug: Acarbose 100
Normalized name: acarbose 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose 100 mg t.i.d.
Study: 8131533
Drug: Oxygen (O2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen (O2, 6 L/min by nasal cannula)
Study: 2480147
Drug: Placebo (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline infusion for 45 min)
Study: 30446246
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg atorvastatin before primary angioplasty (AST)
Study: 18661524
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment alone (ST)
Study: 25731907
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (CWMT and BPT)
Study: 23518863
Drug: 52.5 mL
Normalized name: ALCOHOL 352.5 mL in 500 mL EXTRACORPOREAL LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 52.5 mL of lidocaine 1%
Study: 23518863
Drug: 35 mL
Normalized name: ethanol 0.35 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 mL of lidocaine 1.5%
Study: 23518863
Drug: 26.25 mL
Normalized name: ALCOHOL 26.25 mL TOPICAL CLOTH [Sanitizing Wipes]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 26.25 mL of lidocaine 2%
Study: 18316985
Drug: Separate DTaP
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate DTaP + IPV vaccines
Study: 17137891
Drug: Midodrine hydrochloride
Normalized name: Midodrine Hydrochloride
DrugBank: Midodrine (DB00211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Midodrine hydrochloride as first‐line therapy in addition to conventional therapy
Study: 9200283
Drug: Bismuth-based triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth-based triple therapy (n = 50)
Study: 30153497
Drug: Potentially Inappropriate
Normalized name: Potentilla discolor whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potentially Inappropriate Psychotropic drugs (PIP)
Study: 30153497
Drug: Inappropriate background
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inappropriate background regimen prescription
Study: 30153497
Drug: Inappropriate antidepressant
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inappropriate antidepressant prescription
Study: 30153497
Drug: Inappropriate prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inappropriate prescription of anxiolytics
Study: 30153497
Drug: Inappropriate prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inappropriate prescription of hypnotics
Study: 30153497
Drug: Potentially inappropriate
Normalized name: Potentilla discolor whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potentially inappropriate background regimen prescription
Study: 29202646
Drug: 5 mg/1
Normalized name: Iron 15 MG/1 ML Oral Syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/1 mL diclofenac HPβCD
Study: 29202646
Drug: 12.5 mg/1
Normalized name: pyrilamine 12.5 mg/15 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg/1 mL diclofenac HPβCD
Study: 29202646
Drug: 25 mg/1
Normalized name: Levofloxacin 25 MG/1 ML Oral Syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg/1 mL diclofenac HPβCD
Study: 29202646
Drug: 50 mg/1
Normalized name: Elimite 50 MG/1GM Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/1 mL diclofenac HPβCD
Study: 29202646
Drug: 1 mL
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL placebo
Study: 20298651
Drug: 10% sucrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% sucrose solution
Study: 24636395
Drug: Vitamin D3,
Normalized name: Vitamin D3, 25 mcg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3, 12,000 IU daily for 12 weeks
Study: 18393052
Drug: Methamphetamine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methamphetamine administration
Study: 16581036
Drug: Eszopiclone 3
Normalized name: eszopiclone 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eszopiclone 3 mg co-administered with fluoxetine
Study: 16581036
Drug: Placebo co-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo co-administered with fluoxetine
Study: 31818716
Drug: OLA-guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: OLA-guided therapy
Study: 16850671
Drug: Low-dose monophasic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose monophasic oral contraceptive pills
Study: 2876775
Drug: Tulobuterol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tulobuterol (2 mg BID)
Study: 2876775
Drug: Salbutamol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (2 mg TID)
Study: 8583779
Drug: Epoprostenol infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoprostenol infusion (initial rate of 2 ng/kg/min, increased to max 8 ng/kg/min)
Study: 2248854
Drug: 15 ml
Normalized name: ethanol 0.15 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 ml kg‐1 h‐1 intravenous crystalloid fluid
Study: 2248854
Drug: 5-10 ml
Normalized name: amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-10 ml kg‐1 h‐1 intravenous crystalloid fluid
Study: 2248854
Drug: Low sodium
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low sodium (glucose) solutions
Study: 6988946
Drug: Doxycycline 200
Normalized name: doxycycline 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 200 mg orally 12‐18 hours preoperatively and 200 mg intravenously during the subsequent 4 days
Study: 6988946
Drug: Doxycycline 200
Normalized name: doxycycline 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 200 mg orally 12‐18 hours preoperatively and 200 mg intravenously during the subsequent 4 days + 2 grams of tinidazole orally as a single dose 12‐18 hours preoperatively
Study: 6988946
Drug: Bacitracin/neomycin tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacitracin/neomycin tablets during the 3 days immediately prior to operation
Study: 26296929
Drug: OTO‐201 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: OTO‐201 4 mg
Study: 26296929
Drug: OTO‐201 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: OTO‐201 12 mg
Study: 24482348
Drug: Postoperative prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative prednisone 30 mg daily × 7 days
Study: 24482348
Drug: Postoperative placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative placebo pill daily × 7 days
Study: 23188903
Drug: Peri-articular injection
Normalized name: casanthranol / docusate sodium Oral Capsule [Peri-Colace]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peri-articular injection of local anaesthetic
Study: 15168035
Drug: All solutions
Normalized name: ALCOHOL 0.57 mL in 1 mL / IODINE 0.06 g in 1 mL / POTASSIUM IODIDE 0.05 g in 1 mL / BORIC ACID 0.01 g in 1 mL / SODIUM BORATE 0.002 g in 1 mL TOPICAL LINIMENT [Ball Solutions]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All solutions (WHY, CAHY, C, W)
Study: 10022937
Drug: Systemic antiedema
Normalized name: Drugs used in hereditary angioedema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic antiedema and hemostyptic therapy (Dicynone drg and Reparil drg)
Study: 2189367
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose beclomethasone dipropionate (750 micrograms three times daily for five days)
Study: 2511911
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg twice daily
Study: 389223
Drug: Atenolol (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (any dosage)
Study: 101223
Drug: Atenolol once
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol once daily
Study: 30944686
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg hydromorphone coadministered with ropivacaine (group H1)
Study: 30944686
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg hydromorphone coadministered with ropivacaine (group H2)
Study: 30944686
Drug: 0.6 mg
Normalized name: thymol 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg hydromorphone coadministered with ropivacaine (group H3)
Study: 30944686
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg hydromorphone coadministered with ropivacaine (group H0)
Study: 28288592
Drug: treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment as usual without specific training (tauSTPP)
Study: 25939591
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg resveratrol daily for 4 months
Study: 23297849
Drug: Removable dentures
Normalized name: ALCOHOL,DENATURED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Removable dentures supported with four implants
Study: 23297849
Drug: Fixed reconstruction
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed reconstruction using eight implants
Study: 23297849
Drug: Various implant
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various implant retained and/or supported prostheses
Study: 20571097
Drug: Low-GDP solution
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-GDP solution
Study: 17449110
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of amantadine 100 mg t.i.d. and baclofen 30 mg t.i.d.
Study: 17449110
Drug: Cocaine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine (20 mg and 40 mg doses)
Study: 14680448
Drug: Carvedilol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (mean daily dose 41.8 mg)
Study: 14680448
Drug: Metoprolol tartrate
Normalized name: Metoprolol Tartrate
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol tartrate (mean daily dose 85 mg)
Study: 8749837
Drug: Lofepramine (noradrenaline-specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lofepramine (noradrenaline-specific reuptake inhibitor)
Study: 8749837
Drug: Fluoxetine (serotonin-specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (serotonin-specific reuptake inhibitor)
Study: 27543832
Drug: female‐specific group
Approvals — FDA: no, EMA: no, PMDA: no
Description: female‐specific group or individual outpatient treatment
Study: 22945607
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron supplementation (50 mg, 4 times a week for 8.5 months)
Study: 11232677
Drug: Nasogastric administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nasogastric administration of SOS (40 mg dose)
Study: 11232677
Drug: Jejunal/duodenal administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jejunal/duodenal administration of SOS (40 mg dose)
Study: 11232677
Drug: All routes
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All routes of administration (nasogastric, jejunal, duodenal)
Study: 9490600
Drug: Thyroxine suppressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroxine suppressive therapy
Study: 9490600
Drug: Postoperative thyroxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative thyroxine therapy
Study: 9490600
Drug: Monitoring without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Monitoring without thyroxine treatment
Study: 7817355
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg trandolapril once daily for 30 days (D21 to D50)
Study: 29625762
Drug: PCT and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCT and antidepressants
Study: 6125562
Drug: Antidepressants alone
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants alone
Study: 29625762
Drug: PCT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCT with tapering of antidepressants
Study: 26220763
Drug: Probiotics (Bifidobacterium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (Bifidobacterium lactis, Bifidobacterium longum, or a combination of both)